Page 2 - Choon Lui News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Choon lui. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Choon Lui Today - Breaking & Trending Today

Bintai Kinden teams up with Australia's International Equities to develop Holistica Melaka and Holistica Penang


Bintai Kinden teams up with Australia’s International Equities to develop Holistica Melaka and Holistica Penang
International Equities’ Seasons Botanic Gardens Melbourne. – International Equities Corp website
PETALING JAYA: Bintai Kinden Corp Bhd is teaming up with Australia’s International Equities Corp Ltd to jointly undertake two mixed property development and management projects with healthcare facilities and wellness services in Malacca and Penang.
The company signed a business collaboration agreement with International Equities today.
International Equities is listed on the Australian Securities Exchange. The company’s principal activities are tourism, hotel management, real estate sales and management. Currently, it owns and operates hotels and apartments under the brand and/or trademark of “Seasons”, namely Seasons Botanic Gardens Melbourne, Seasons Heritage Melbourne, Seasons Darling Harbour Sydney and Seasons of Perth. ....

Western Australia , New South Wales , Malaysia General , Choon Lui , Holistica Melaka , Bintai Kinden , Australia International Equities Corp Ltd , Bintai Kinden Corp Bhd , Australian Securities Exchange , International Equities , International Equities Corp Ltd , Australian Securities , Seasons Botanic Gardens Melbourne , Seasons Heritage Melbourne , Seasons Darling Harbour Sydney , Holistica Penang , Ong Choon Lui , மேற்கு ஆஸ்திரேலியா , புதியது தெற்கு வேல்ஸ் , மலேசியா ஜநரல் , சூன் லு , ஹோலிஸ்டிகா மேலாக , ஆஸ்திரேலியா சர்வதேச பங்குகள் கார்ப் லிமிடெட் , ஆஸ்திரேலிய பத்திரங்கள் பரிமாற்றம் , சர்வதேச பங்குகள் , சர்வதேச பங்குகள் கார்ப் லிமிடெட் ,

Still some ways to go for Malaysian companies' vaccine distribution biz to take off


KUALA LUMPUR (Jan 12): Promising developments on the vaccine front have stirred investor interest in companies that venture into vaccine distribution, in hopes they will be in for bumper profits.
However, it is not clear at this juncture just how much or when these companies can cash in, given just the evaluation process alone for a vaccine to be approved for distribution and use in Malaysia will take five phases. The first phase alone which is the checking of the vaccine dossiers or research documents typically takes between 90 and 120 days, according to the Ministry of Health (MoH).
When contacted, property developer Yong Tai Bhd chief executive officer Datuk Wira Boo Kuang Loon said the company expects to bring its Chinese partner s vaccine into Malaysia by the third quarter of this year, at the earliest, on obtaining approval from the MoH s National Pharmaceutical Regulatory Agency (NPRA). Any vaccines or medicines to be imported into Malaysia for use here will req ....

Kuala Lumpur , Yong Tai , New Zealand , Choon Lui , Bintai Kinden , Nugenerex Immuno , Yong Tai Bhd , Kinsel Sdn Bhd , Genting Bhd , Solution Group Bhd , Nusankota Development Sdn Bhd , Bintai Kinden Corp Bhd , Generex Biotechnology Corp , Sports Ltd , My Eg Services Bhd , Kanger International Bhd , Bintai Holdingsm Sdn Bhd , Oncology Inc , Shenzhen Kangtai Biological Products Co Ltd , Moh Ethics Committee , Ministry Of Health Mo , Moh National Pharmaceutical Regulatory Agency , Datuk Wira Boo Kuang Loon , National Pharmaceutical Regulatory Agency , Ethics Committee , Nugenerex Immuno Oncology Inc ,

Bintai Kinden's partner files trademark for Covid-19 vaccine


’s partner Generex Biotechnology Corporation has filed for a trademark for its li-Key vaccine and patent for its Ii-Key-SARS-CoV-2 vaccine.
In a statement issued on Thursday, Bintai Kinden said the Ii-Key vaccine was designed to be a complete vaccine for the Covid-19.
“The technology offers the safest and best route for the rapid development of a Covid-19 vaccine, ” it said.
It explained the complete vaccine is designed to regulate the immune system to provide a targeted, neutralising antibody response.
Bintai Kinden managing director Ong Choon Lui said Generex’s Covid-19 vaccine was based on the results of the ex-vivo human studies. It will be formulated for phases one and two clinical trials. ....

Kuala Lumpur , New Zealand , East Timor , Republic Of , Choon Lui , Sdn Bhd , Generex Covid , Nugenerex Immuno , Bintai Kinden , Oncology Inc , Generex Biotechnology Corporation , Bintai Kinden Corporation Bhd , Bintai Kinden Corporation , Ong Choon Lui , Nugenerex Immuno Oncology Inc , Healthcare Sdn Bhd , Corporate News , Covid 19 , Generex Biotechnology , குவாலா லம்பூர் , புதியது ஜீலாந்து , கிழக்கு டைமர் , குடியரசு ஆஃப் , சூன் லு , ஸ்டன் ப்ட் , புற்றுநோயியல் இன்க் ,